Recommended

Teva close to API business sale
Streamlined rAAV purification enables efficient upstream analytics – access now
First new IPF treatment in US for a decade
Webinar: Radiopharmaceuticals’ time-to-result challenge
AstraZeneca/Daiichi cancer drug boost
Takeda to move away from cell therapy
GSK appoints new CEO
news

Ophthalmology acquisition to advance tri-specific antibody

0
SHARES

A novel late-phase clinical candidate for diabetic macular edema and neovascular age-related macular degeneration will be developed as part of the proposed agreement.

acquisition Eyebio

Merck (known as MSD outside of the US and Canada) plans to acquire Eyebiotech Limited, with the aim to advance development of novel treatments for vision disorders. The deal has a potential value of $3 billion. Under the terms of the acquisition, Merck, through a subsidiary, will acquire all outstanding shares of EyeBio. The total sum comprises of a $1.3 billion upfront payment and up to $1.7 billion in future milestone payments.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

the acquisition significantly expands Merck/MSD’s presence in ophthalmology”

In addition to augmenting MSD’s pipeline, this new acquisition “significantly expands” its presence in ophthalmology, the company noted. 

EyeBio highlighted that its pipeline consists of drug candidates being developed to prevent and treat vision loss associated with retinal vascular leakage.

A promising biologic

EyeBio’s lead candidate, Restoret™ (EYE103), is an investigational, potentially first-in-class tetravalent, tri-specific antibody. The medicine works “as an agonist of the Wingless-related integration site (Wnt) signalling pathway”, the company stated.

Restoret is given via an intravitreal injection, with the aim to restore and preserve the blood-retinal barrier in the eye.

The treatment is expected to advance into a pivotal Phase IIb/III trial in diabetic macular edema in the second half of 2024. This is based on positive results from the Phase Ib/IIa AMARONE study in diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD).

Advancing the acquisition

“By combining our strengths, we aim to advance with rigor and speed the development of their promising pipeline of candidates targeting retinal diseases,” stated Dr Dean Li, President, Merck Research Laboratories.

“As a subsidiary of Merck, EyeBio will be positioned to tap into the resources and infrastructure needed to support the clinical, regulatory and commercial development of these candidates and help bring them to patients worldwide,” Dr David Guyer, Chief Executive Officer and President, EyeBio explained.

The proposed acquisition of EyeBio will close subject to certain approval and other customary conditions. MSD anticipated that the deal will be completed in the third quarter of 2024.

Share via
Share via